Robert Langer: From MIT ChemE PhD to America's Youngest Triple Academy Member and Founder of 40+ Biotech Startups

It is hard to imagine that one day we would need to use data-driven analysis to assess an individual’s impact on the global healthcare innovation industry, but if that person is Robert Langer, it makes perfect sense.

Langer is hailed asThe Most Important Scientists in Biotechnology Who Can Change the Future, and also a great inventor and entrepreneur. He isOne of the Most Cited Researchers in the World, he is also a prolific entrepreneur,Participated in the founding of over 40 biotechnology companies. Langer's research laboratory at the Massachusetts Institute of Technology isThe World's Largest Biomedical Engineering Laboratory。

He is one of the most closely watched scientists in academia and industry. His talent emerged early, yet he achieved late-blooming success at age 40, becoming the youngest triple academy member in the United States at 47. The first half of Langer’s life has been both turbulent and legendary.

In the autumn of 1948, this great scientist was born into an ordinary family in Albany, the capital of New York State. His father operated a billiard hall and a small bar. At the age of 10, Langer was fascinated by the microscopic world under the microscope and enjoyed tinkering with various small robots. His father would bring home magical little gadgets and helped him set up aMy First Laboratory in Life。

During his middle school years, Langer’s talents began to emerge. Although he was not adept at literature-related courses, he consistently ranked at the top of his class in science and mathematics. Upon graduation, he enrolled at Cornell University, majoring in chemical engineering, his field of greatest interest.

In 1974, the United States faced its first oil crisis. The outbreak of the Fourth Arab-Israeli War led to an oil embargo, with the Organization of the Petroleum Exporting Countries (OPEC) announcing a suspension of oil exports, causing global oil prices to surge. Against this backdrop, the U.S. economy suffered a severe blow, with GDP declining by 4.7%. The ensuing inflation further contracted the U.S. economy, forcing then-President Nixon to declare a national state of emergency.

And in that year, Langer happened to be fromPh.D. in Chemical Engineering, Massachusetts Institute of Technology. Chemical engineering plays a crucial role in improving the efficiency of oil extraction and refining, making chemical engineers like Langer highly sought-after. However, Langer made what was considered a very “rebellious” decision at the time, rejecting offers from several companies in one go, including the world’s largest oil companyExxonincluding 20 oil companies that have extended olive branches, intending to enter the healthcare sector. It is important to note that,At that time, the unemployment rate in the United States had risen to around 8%.。

However, how could Langer, who had no prior experience in the medical field, persuade these employers? The answer is that he couldn’t; the anticipated turnaround never materialized. He sent job application letters to more than 40 medical schools, only to receive no response whatsoever. Undeterred, he then set his sights on hospitals, but again met with no success.

At this time, a person namedJudah Folkman'sSomeone turned the tide, and Langer entered his laboratory through a friend’s referral.

Folkman first proposed in 1973 that"Tumor growth and metastasis depend on angiogenesis"hypothesis, attempting to conduct cancer treatment research using unconventional methods. In his laboratory, Langer seamlessly integrated his experience and knowledge in chemical engineering with medical research. He proposedDrug Delivery and Release Using Polymeric Compounds, capable of entering tumor lesions to inhibit angiogenesis. To realize this concept, the compound must meet two criteria: tumor targeting and drug delivery with sustained release.

Drawing on his experience in chemical engineering, he proposed that drugs could be encapsulated using polymer materials, enabling sustained release through the interstices of the material upon reaching the target site.

Atoms within molecules are connected by covalent bonds. Covalent bonds are formed through electrostatic interactions between atoms; the bond energy of covalent bonds varies among different elements, leading to differences in molecular stability. Polymers generally have high molecular weights, and some molecules degrade over time. This degradation may occur only on the molecular surface or simultaneously on the surface and within the interior of the molecule; the latter is known as bulk degradation. This class of polymer compounds is unsuitable, as it can lead to premature drug release.

Unfortunately, at that timeThe Only FDA-Approved Polymer Compound Is a Two-Dimensional Polymer, specifically biodegradable materials. However, for Langer, who had a background in chemical engineering, synthesizing a new polymer compound was by no means a challenge. He also drew inspiration from computer chip manufacturing and collaborated with computer engineering experts to fabricate numerous microscopic drug reservoirs on computer chips. These reservoirs were sealed with small metal flaps at their edges to prevent drug leakage. Upon reaching the target site, the drug could be released by applying an electric current to rupture the metal seals.

This may be the world’s first microprocessor to achieve controlled drug release, integrating chemistry, pharmacy, and computer engineering. While it seems like a whimsical idea today, it appeared nothing short of fantastical at the time. His achievementsFacing Severe Skepticism from the Academic Community, even though he has repeated it hundreds of times; he toAll Applications Submitted to the NIH (National Institutes of Health) Were Rejected, which has also affected applications for faculty positions.

Those who succeed never give up easily, and Langer was no exception. Although he could only reluctantly accept a temporary position in an MIT science program after completing his postdoctoral fellowship, Langer never abandoned his career in medical research. Everyone thought he was talking nonsense; the NIH believed that such compounds could not be synthesized at all; the Patent Office deemed the technology unfeasible and rejected his application five consecutive times; even private companies were unwilling to engage with him, despite the fact that he had finally obtained the patent.

After repeatedly hitting walls, Langer had no choice but to take the final path: starting a business. In 1987, after much difficulty in securing a research grant, Langer and his friend founded a technology company focused on drug delivery, the renownedEnzytech！

All obstacles were, in fact, guiding you toward the right path.

In 1988, the academic community recognized Langer’s achievements, and his status at MIT changed from a temporary employee to a tenured professor.That year, Langer was 40 years old., is gradually entering his prime. Between 1996 and 2021, he received more than 220 major awards, including the U.S. National Medal of Science and the National Medal of Technology and Innovation (the highest honors in American science; currently, there are only three living recipients who have received both awards, and Langer is one of them).

Furthermore, Langer has published more than 1,500 papers, holds over 1,400 patents, and participated in the founding of more than 40 biotechnology companies. Industry insiders have jokingly remarked that “his first-rate achievements become patents, second-rate ones are published in Nature, and third-rate ones appear in other top-tier journals.” He is one of the most highly cited researchers worldwide and a legendary figure in the field of biotechnological innovation.

Langer is an outstanding scientist and inventor, as well as a highly successful entrepreneur. As previously mentioned, he has participated in the founding of more than 40 biotechnology companies. Not all of these ventures were based on his own inventions and research; Langer has developed his own approach to the commercialization of innovative technologies.

Initially, Langer followed the most direct path to commercialization: he monetized his research by founding a company, which was later acquired by a larger corporation. With the proceeds, he resumed his research and established new companies. We shall tentatively refer to this as“Langer Type I”, representative companies during this period include the first company Enzytech, biomaterials companies Neomorphics and Focal, porous microsphere technology companies Enzymed and Acusphere...

After a few successful deals, Langer grew familiar with the investors. Thus came"Langer Type II": Langer contributes ideas, while investors provide capital. When a new idea emerges, Langer calls the investors; if they deem the concept feasible, they will fund his research.

This approach has helped Langer found numerous companies and delivered substantial returns to investors. More than 20 companies established through this model have achieved successful exits, predominantly via initial public offerings or acquisitions by major pharmaceutical firms.

Meanwhile, capital infusion has propelled “Langer-style innovation” to new heights. On one hand, an increasing number of postdoctoral researchers and investors are drawn by its reputation; on the other, some researchers, upon achieving results, seek Langer’s expert review through intermediaries. Thus, “"Langer's Three Types"It was born: After evaluating the research findings, if Langer deemed them promising, he would present them to investors. If the investors responded favorably, the project would receive dual endorsement from both the investment firm and Langer.

Under this model,Langer is not only playing the roles of a scientist and an entrepreneur, but also transitioning into an investor.

The most representative company in this model is calledModerna。

Unparalleled achievements have made Langer synonymous with success and high-level innovation; any company he joins garners significant attention from investors and commands a higher valuation in fundraising. Consequently, some technology-driven startups proactively invite Langer to join their teams, which is"Langer's Four Types"。

Moreover, Langer’s achievements and methodologies in translating scientific research into practical applications have profoundly influenced his many protégés. This group includes Harvard University’s biomaterials luminary David J. Mooney; Molly Stevens, Director of the Biomedical Materials Science Laboratory at Imperial College London; Ali Khademhosseini, Professor at the Massachusetts Institute of Technology and Associate Editor of ACS Nano; and Antonios G. Mikos, Member of the U.S. National Academy of Engineering. Each of these individuals is regarded as a preeminent leader in their field.

Excellence is a magnetic force; throughout his professional journey in innovation and translation, Langer has also connected with a group of equally outstanding partners and friends.

Alex KlibanovHe is a dual member of the U.S. National Academy of Sciences and the National Academy of Engineering, with significant contributions in fields such as enzyme catalysis, new materials, and macromolecular drug delivery systems. This Russian native of Moscow moved to the United States in 1991, engaging in academic research and industrial work, with research interests focused on chemical applications in biomedical research.

Klibanov met Langer during a low point in the latter’s career, and the two co-founded Enzytech. Subsequently, Klibanov went on to establish six additional pharmaceutical companies and served as a scientific advisor or director for numerous pharmaceutical, medical device, and biotechnology firms, as well as for law firms specializing in pharmaceutical patent litigation.

George ChurchHe is a close confidant of Langer. The former, hailed as the “Godfather of Genomics,” is one of the world’s leading geneticists. Seven years his junior, Langer shares with him many similarities, including their vegetarian lifestyle. Like Langer, Church holds professorships at both Harvard University and the Massachusetts Institute of Technology (MIT), embodying the dual roles of scientist and entrepreneur.

He has participated in the founding of 22 biotechnology companies, such as Veritas Genetics, Nebula Genomics, and eGenomics, and has provided consulting services to sequencing companies including BGI, Life Technologies, Illumina, Danaher Corporation, Roche Diagnostics, Pacific Biosciences, Genia, and Nabsys. Church has had a profound impact on China’s gene technology sector, with influential Chinese scientists and entrepreneurs such as Luhan Yang, Kun Zhang, and Yuan Gao being his students.

They share similar experiences and equally unparalleled achievements. Individually, they each reign supreme; should they ever collaborate, they would undoubtedly become “invincible.”

Terrance McGuireHe is a co-founder of Polaris Partners, one of the earliest investment firms to establish close ties with Langer and a key partner in the “Langer Model II” translation framework. Langer frequently calls McGuire with promising ideas. McGuire himself has many years of experience investing in early-stage healthcare and information technology; prior to founding Polaris Partners, he spent seven years at Burr, Egan, Deleage & Co.

Based on the “Langer Model II” incubation framework, Langer and Polaris Partners have founded more than 20 companies, with Mr. McGuire himself serving as a board member at multiple firms, including Acceleron and Trevena.

Noubar Afeyan, Founder and CEO of Flagship Ventures. Unlike traditional venture capital firms, Flagship Ventures specializes in creating and incubating startups based on internally developed intellectual property. It was this very philosophy that brought Langer and Flagship Ventures together, forged a friendship with Afeyan, and ultimately led to the founding of Moderna, propelling it to its current stature.

Furthermore, Noubar was a founding team member, director, and investor in several successful companies, including Chemgenics Pharmaceuticals (acquired by Millennium Pharmaceuticals), Color Kinetics (acquired by Philips), Adnexus Therapeutics (acquired by Bristol-Myers Squibb), and Affinnova (acquired by AC Nielsen). Over his 28-year career as an inventor, entrepreneur, CEO, and venture capitalist, Noubar helped establish more than 35 successful life sciences and technology startups.

“Lofty as towering mountains, vast as flowing rivers,” McGuire and Afeyan were more like Zhong Ziqi in Langer’s career. Their support greatly accelerated Langer’s path to success, helping him turn one inspiration after another into reality. Now 74 years old, Langer holds assets worth over $1.8 billion, ranking 1,931st on the 2021 Forbes Global Billionaires List.Ranked by Nature Biotechnology as the World’s Leading Figure in Translational Research。

Today, Langer remains deeply devoted to scientific research. He typically participates in the founding of companies as a scientific advisor, board member, or technology licensor, but he is generally not involved in their day-to-day operations. His laboratory spans more than 1,900 square meters and brings together over a hundred top-tier researchers. In this interdisciplinary institute, innovation continues to operate steadily and efficiently, and Langer’s legend lives on....